Posted by Michael Wonder on 21 Jul 2020
Grünenthal and Averitas Pharma announce U.S. FDA approval of Qutenza for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet
21 July 2020 - Qutenza is the first and only topical, non-systemic, non-opioid pain treatment of its kind to deliver prescription strength capsaicin directly into the skin.
Grünenthal announced today that its U.S. subsidiary Averitas Pharma received U.S. FDA approval for Qutenza (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults.
Qutenza is a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch and is the first and only treatment of its kind to deliver prescription strength capsaicin directly into the skin.
